Clinical Trials Browser

Phase 2 × Leukemia × Sorafenib × Clear all

NCT02196857 2020-01-14

Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD Mutation

Phase 2 Completed

16 enrolled 8 charts

Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute